Isophorone diamine (IPDA) is a colorless to pale yellow liquid that is a versatile monomer used in the production of various polymers, including polyamides, polyurethanes, and epoxy resins. It is synthesized through a multi-step process involving the reaction of isophorone with ammonia and hydrogen. IPDA is known for its excellent adhesion properties, high thermal stability, and good chemical resistance. It is commonly used in coatings, adhesives, and sealants due to its ability to form strong, durable bonds. The compound exhibits high reactivity, which contributes to its widespread applications. The synthesis and properties of IPDA have been extensively studied due to its importance in the chemical industry. The research on IPDA focuses on optimizing its synthesis, exploring new applications, and enhancing its performance characteristics. The study of IPDA is driven by the need to develop advanced materials with improved properties for various industrial applications.'
isophorone diamine: curing agent for polymers; structure given in first source; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 17857 |
| CHEMBL ID | 1876029 |
| SCHEMBL ID | 15383 |
| SCHEMBL ID | 8745864 |
| MeSH ID | M0150172 |
| Synonym |
|---|
| LS-13908 |
| un2289 |
| cyclohexanemethylamine, 5-amino-1,3,3-trimethyl- |
| ccris 6680 |
| 5-amino-1,3,3-trimethylcyclohexanemethylamine |
| einecs 220-666-8 |
| isophoronediamine |
| 3-aminomethyl-3,5,5-trimethylcyclohexylamine |
| isophorone diamine |
| hsdb 4058 |
| NCGC00164044-01 |
| 2855-13-2 |
| 3-(aminomethyl)-3,5,5-trimethylcyclohexanamine |
| cyclohexanemethanamine, 5-amino-1,3,3-trimethyl- |
| 3-(aminomethyl)-3,5,5-trimethylcyclohexan-1-amine |
| araldite hy 5083 |
| 5-amino-1,3,3-trimethylcyclohexanemethanamine |
| vestamin ipd |
| 1-amino-3-aminomethyl-3,5,5-trimethylcyclohexane |
| I0228 |
| AKOS000120367 |
| NCGC00164044-02 |
| x5wya841bu , |
| unii-x5wya841bu |
| isophoronediamine [un2289] [corrosive] |
| ec 220-666-8 |
| dtxcid907503 |
| cas-2855-13-2 |
| NCGC00257083-01 |
| dtxsid6027503 , |
| tox21_303122 |
| tox21_201401 |
| NCGC00258952-01 |
| isophorondiamine |
| FT-0627445 |
| ipda |
| SCHEMBL15383 |
| 1-amino-3-aminomethyl-3,5,5-trimethyl cyclohexane |
| 1-amino-3,3,5-trimethyl-5-aminomethyl cyclohexane |
| 1-aminomethyl-5-amino-1,3,3-trimethyl cyclohexane |
| SCHEMBL8745864 |
| CHEMBL1876029 |
| 1-amino-3,3,5-trimethyl-5-aminomethylcyclohexane |
| 3-aminomethyl-3,5,5-trimethyl cyclohexylamine |
| 1-amino-3-(aminomethyl)-3,5,5-trimethylcyclohexane |
| 3,3,5-trimethyl-5-aminomethylcyclohexylamine |
| 3-(aminomethyl)-3,5,5-trimethylcyclohexanamine # |
| 1,3,3-trimethyl-1-aminomethyl-5-aminocyclohexane |
| un 2289 |
| F2191-0270 |
| mfcd00019397 |
| J-017123 |
| Q1674522 |
| EN300-20211 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 27.7231 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259394 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 24.7082 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 113.0495 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 36.8180 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.8945 | 0.0002 | 29.3054 | 16,493.5996 | AID1259383 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 1.7374 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 89.1251 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 61.1306 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (43.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (5.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 10 (50.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (45.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||